PFC
PCRX icon

Phocas Financial Corp’s Pacira BioSciences PCRX Stock Holding History

Phocas Financial Corp’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-114,413
Closed -$2.59M – 164
2026
Q1 		$2.59M Sell
114,413
-32,122
-22% -$714K 0.41% 103
2025
Q4 		$3.79M Sell
146,535
-368
-0.3% -$8.75K 0.49% 84
2025
Q3 		$3.79M Sell
146,903
-46,534
-24% -$1.14M 0.49% 81
2025
Q2 		$4.62M Buy
193,437
+50,994
+36% +$1.29M 0.66% 69
2025
Q1 		$3.54M Buy
+142,443
New +$3.41M 0.54% 76
2023
Q4 		– Sell
-44,131
Closed -$1.35M – 182
2023
Q3 		$1.35M Sell
44,131
-89,064
-67% -$3.21M 0.2% 122
2023
Q2 		$5.34M Buy
133,195
+36,839
+38% +$1.52M 0.73% 58
2023
Q1 		$3.93M Buy
96,356
+942
+1% +$37.5K 0.56% 76
2022
Q4 		$3.68M Sell
95,414
-29
-0% -$1.41K 0.53% 81
2022
Q3 		$5.08M Buy
95,443
+3,028
+3% +$168K 0.79% 53
2022
Q2 		$5.39M Sell
92,415
-1,033
-1% -$67.7K 0.81% 58
2022
Q1 		$7.13M Buy
+93,448
New +$6.23M 0.89% 40

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Phocas Financial Corp's PCRX Position: Q2 2026 in Review

Phocas Financial Corp sold out of Pacira BioSciences (PCRX) in Q2 2026, closing a stake of 114,413 shares — an estimated $2.59M sold.

Phocas Financial Corp first reported a position in PCRX in Q1 2022 and held it in 12 quarters. The position peaked at $7.13M in Q1 2022. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Phocas Financial Corp reported no remaining Pacira BioSciences position as of Q2 2026 after selling out during the quarter.
  • Phocas Financial Corp sold 114,413 Pacira BioSciences shares in Q2 2026, an estimated $2.59M.
  • Phocas Financial Corp first reported a position in Pacira BioSciences in Q1 2022 and held it in 12 quarters.
  • Phocas Financial Corp's Pacira BioSciences position peaked at $7.13M in Q1 2022.
  • 253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Phocas Financial Corp's 13F filing for Q2 2026, filed 31 Jul 2026.